Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 13, 2023
Deals

June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review

Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more
BioCentury | Jun 1, 2023
Data Byte

At least 15 PDUFA dates on FDA’s calendar for June

Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | May 23, 2023
Deals

Sizing up VectivBio’s takeout premium among '23 M&A deals

Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Apr 21, 2023
Product Development

ADC advances at AACR: target diversity, optimizing internalization

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Dec 3, 2022
Finance

Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal

Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Sep 9, 2022
Product Development

China driving solid tumor CAR T innovation

Chinese investigator-initiated trials are accelerating CAR T innovation, bringing solid tumor advances to ESMO22
BioCentury | Feb 18, 2022
Product Development

Feb. 17 Quick Takes: Agios wins FDA approval in rare anemia

Plus updates from Arvinas, BMS, Innovent, Ironwood, Deerfield, Yumanity
BioCentury | Jan 18, 2019
Clinical News

China approves Linzess for IBS-C

BioCentury | Dec 21, 2018
Company News

Bausch named 'stalking horse' in Synergy auction

Items per page:
1 - 10 of 205